All Blogs

Apr 08, 2022

Understanding the Chronic Obstructive Pulmonary Disease Increasing Prevalence and Trends


Apr 07, 2022

Aidoc’s Pneumothorax; Cook Medical’s Zenith Thoraco+ Endovascular System; GRAFIX Membrane Study; Corvia’s REDUCE LAP-HF II Trial Results; GE Healthcare and Imeka’s Collaboration; Bioventus to Acquire CartiHeal


Jun 30, 2025

The Rise of Blockchain in Healthcare: How It’s Revolutionizing the Industry


Apr 05, 2022

Precigen’s PRGN-3006; Yescarta Approved as a First CAR T-cell Therapy for R/R LBCL; Biogen & Ionis’ BIIB078; Nobelpharma’s HYFTOR (sirolimus topical gel) 0.2%; Cerevance Parkinson’s Drug; Sanofi & Regeneron’s Dupixent; Clovis’s Rubraca for Ovarian Cancer; Immunocore Eye Cancer Cell Therapy Approval


Apr 04, 2022

LAG 3: A Promising Next Generation Cancer Immunotherapy


Apr 01, 2022

Treatment-resistant Hypertension: Insights into the Challenges and Solutions


Mar 31, 2022

Ypsomed-CamDiab’s Collaboration; Vela Diagnostics’s NGS-Based Pan-Cancer Panels; Fresenius’s SMOFlipid Lipid Injectable Emulsion; Sientra Gained Regulatory Nod to Market Breast Implants; Synchron’s Endovascular BCI Stentrode Device; HLT’s TAVR Clinical Studies


Mar 30, 2022

Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022


Mar 29, 2022

Sanofi’s Rare Disease Drug Xenpozyme’ Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB’s FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval


Mar 28, 2022

Examining the Therapeutic Advances in Fabry Disease Treatment Landscape